Skip to content

Metabonomics for Predicting Early Use of Immunoglobulin in Anti-NMDAR Encephalitis

Metabonomics for Predicting Early Use of Immunoglobulin in Anti-NMDAR Encephalitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025188
Enrollment
Unknown
Registered
2019-08-15
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-NMDAR Encephalitis

Interventions

group of good curative effect of hormone + group of bad curative effect of hormone (group of good curative effect of IVIg + group of bad curative effect of IVIg):Glucocorticoids + IVIg

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or above; 2. All patients met the diagnostic criteria agreed by Chinese experts in the diagnosis and treatment of autoimmune encephalitis: (1) Within 3 months, one or more of the six following major groups of symptoms occurred: abnormal (psychiatric) behavior or cognitive dysfunction, speech dysfunction, seizures, movement disorder, decreased level of consciousness, autonomic dysfunction, or central hypoventilation; (2) Positive results of anti-NMDAR antibodies in CSF; (3) Reasonable exclusion of other causes. 3. Patients who have signed an informed consent.

Exclusion criteria

Exclusion criteria: 1. HIV infection, meningitis, brain abscess, prion diseases, cerebral malaria, brain tumor, or a diagnosis of a noninfectious central nervous system disease, such as acute demyelinating encephalomyelitis (ADEM); 2. Patients with laboratory evidence of infectious encephalitis, for example, viral, bacteria, mycobacterium tuberculosis (TB), parasitic, or fungal; 3. Patients diagnosed with epilepsy, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis; 4. Patients with coexisting other positive autoimmune or neurologic paraneoplastic antibodies; 5. Pregnant women, lactating women, and women of childbearing age who are not willing to receive contraception during the first 4 weeks of admission and throughout the study period.

Design outcomes

Primary

MeasureTime frame
Anti-NMDAR titer;Metabonomics;

Secondary

MeasureTime frame
Seizure duration;Duration of mental symptoms;GOS;mRS??;28-day survival rate;Length of stay in ICU;Length of mechanical ventilation;All-cause mortality rate;

Countries

China

Contacts

Public ContactFu Min

Intensive Care Unit, West China Hospital, Sichuan University

310636741@qq.com+86 13982233067

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026